Event Event

ASH 2026

December 12 - December 15, 2026

New Orleans, Louisiana

Request a meeting

The ASH Annual Meeting is considered the premier global event in hematology (the study and treatment of blood disorders and blood cancers), with more than 30,000 attendees, representing 26,000 hematology professionals from more than 100 countries. It is the largest and most comprehensive meeting in the field, showcasing the latest scientific discoveries, clinical research, treatment advances, and emerging therapies. Among attendees include: hematologists, oncologists, bone marrow transplant physicians, pathologists, NP, PA, pharmacists, and other allied health professionals, pharma and biotech companies.

Connect with Parexel's experts at booth #2457, during the event. We'll be onsite and ready to discuss your needs. You can also schedule a meeting in advance via the link below. You can also schedule a meeting with our team, in advance via the link below.

Jingke Yang

Senior Medical Director, Cell & Gene Therapy

Session name – 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials
Title – Immortal-time bias and upfront autologous stem-cell transplantation in peripheral T-cell lymphoma: A national landmark analysis
Date – Monday, December 14, 2026, from 10:45 - 11 a.m.

Poster presentations:

Session name –  906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Title – Secondary mature T/NK-cell lymphomas following CD19 CAR-T therapy were observed exclusively among patients with prior alkylator exposure: A real-world EHR analysis
Author – Maiti Kausik
Date – Saturday, December 12, 2026, from 5:30 – 7:30 p.m.

Session name –  906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Title – Incidence and prognostic impact of venous thromboembolism in newly diagnosed peripheral T-cell lymphoma: a real-world cohort study
Authors –  Vladimir Otasevic1, Darko Antic2,3, Lanzhu Yue1, Maria Ahmad1, Kausik Maiti1, Nancy Lunney1, Darko Dabic1, Chris Learn1, Heidi Cho1
Date – Sunday, December 13, 2026, from 6 – 8 p.m.

Session name –  654. Multiple Myeloma: Pharmacologic Therapies: Poster III
Title – Real-world Overall Survival Comparison of BCMA-targeted CAR-T versus Bispecific Antibody in Relapsed/Refractory Multiple Myeloma Patients with Severe Renal dysfunction
Authors – Ying Li, Lanzhu Yue, Heidi Cho
Date – Monday, December 14, from 6 – 8 p.m. 
 

Request a meeting

Are you interested in meeting with our experts at this event? Please fill out the form below, and we'll contact you with more details.